All Updates

All Updates

icon
Filter
Partnerships
Guardant Health expands its partnership with Merck KGaA to expand the use of its database platform
Precision Medicine
Aug 31, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Product updates
Funding
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Aug 31, 2022

Guardant Health expands its partnership with Merck KGaA to expand the use of its database platform

Partnerships

  • California-based precision oncology company Guardant Health has extended its partnership with science and technology company Merck KGaA to leverage its database platform GuardantINFORM. The platform will be used by Merck KGaA to speed up drug discovery and development processes to treat cancer. 

  • GuardantINFORM, a real-world evidence (RWE) platform, comprises over 225,000 clinical and genomic data of patients obtained through the company’s Guardant360 liquid biopsy tests that identified more than 60 types of solid tumor cancers. Under the partnership, Merck KGaA will work with data scientists at Guardant Health on its oncology pipeline using the RWE platform. 

  • Germany-based Merck KGaA operates its biopharmaceutical business in US and Canada as EMD Serono. The company’s healthcare expertise includes areas such as oncology, neurology and immunology, fertility, endocrinology, and general medicine. Further, it builds on strategic partnerships to grow its US business with focused therapies. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.